Quick Answer
Lexaria Bioscience Corp. reported Revenue From Contract With Customer Excluding Assessed Tax of $384.5 thousand for the year ending 2020.
- Lexaria Bioscience Corp. showed an increase of +72.7% in Revenue From Contract With Customer Excluding Assessed Tax from 2019 to 2020.
- This data is from Lexaria Bioscience Corp.'s annual report (Form 10-K), filed with the SEC on October 15, 2020.
- XBRL data for this metric is available from 2018 to 2020 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: $24.6 thousand | Q1 2018: $172.0 thousand | Q2 2018: $140.3 thousand | Q4 2018: $22.2 thousand | Q1 2019: $15.3 thousand | Q2 2019: $59.9 thousand | Q4 2019: $10.3 thousand | Q1 2020: $37.5 thousand | Q2 2020: $36.4 thousand | Q4 2020: $295.7 thousand | Q1 2021: $192.0 thousand | Q2 2021: $204.1 thousand.
- Over the full 3 years of available data (2018 to 2020), Lexaria Bioscience Corp.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 11.2%.
- Historical annual values: Fiscal year 2020: $384.5 thousand | Fiscal year 2019: $222.6 thousand | Fiscal year 2018: $433.3 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: